January 27, 2023
Article
"We noted in our overall population, which was about 214 women, there was a 40% discontinuation rate for Botox treatments in the office," says Katherine L. Woodburn, MD.
January 05, 2023
Machine learning isn’t new to medicine or to urology, but its potential remains largely untapped, according to the authors of two new Cleveland Clinic–led studies.
November 22, 2022
The pharmacokinetic drug GEMTESA, developed by Urovant Sciences, was given to adult patients as a single 75-mg dose in a phase 1 study.
November 04, 2022
Video
“The takeaway is that sacral neuromodulation works well for men with overactive bladder and fecal incontinence, but perhaps less well for pelvic pain. We should see it as one of many multimodal treatments that we could offer for men with chronic pelvic pain,” says Dr. Elterman.
October 28, 2022
“With this study, we gained a better understanding of the features of third line therapy for overactive bladder, that patients find favorable and unfavorable,” says Anjali Kapur, MD.
October 24, 2022
“We wanted to help provide an understanding of what factors guide patient choice of third line therapy for overactive bladder,” says Anjali Kapur, MD.
October 20, 2022
eCoin is a new technology for the management of bladder overactivity that is implanted near the posterior tibial nerve subcutaneously.
October 13, 2022
“Even though this is a really large study, and it appears that vitamin D may not be a sole contributor to improving urinary incontinence or overactive bladder, there may be a subgroup of men who could potentially respond,” says Alayne Markland, DO.
October 03, 2022
“We did not happen to find that vitamin D compared to placebo lowered the odds of having incontinence at year 2 or year 5. Nor did it lower the odds of having overactive bladder symptoms at year 5,” says Alayne Markland, DO.
September 21, 2022
In this interview, Howard Goldman, MD, discusses the development of sacral neuromodulation as a treatment for overactive bladder (OAB).
